Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Netoglitazone

Next Previous
X
Search
Drug Profile

Netoglitazone

Alternative Names: Isaglitazone; MCC-555; RWJ-241947

Latest Information Update: 10 Feb 2010

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Pharma Corporation; Perlegen Sciences
  • Class Antihyperglycaemics; Antihyperlipidaemics; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 11 May 2006 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (PO)
  • 15 Apr 2005 Perlegen Sciences and Mitsubishi Pharma Corporation entered into an exclusive worldwide (except Asia) licensing agreement for the late-stage development and commercialisation of netoglitazone for the treatment of type 2 diabetes and other metabolic disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top